HCW Biologics Statistics

Total Valuation

HCW Biologics has a market cap or net worth of $7.84 million. The enterprise value is $20.67 million.

Market Cap	7.84M
Enterprise Value	20.67M

Important Dates

The next estimated earnings date is Wednesday, August 13, 2025, after market close.

Earnings Date	Aug 13, 2025
Ex-Dividend Date	n/a

Share Statistics

HCW Biologics has 1.74 million shares outstanding. The number of shares has increased by 12.11% in one year.

Current Share Class	1.74M
Shares Outstanding	1.74M
Shares Change (YoY)	+12.11%
Shares Change (QoQ)	+5.61%
Owned by Insiders (%)	39.50%
Owned by Institutions (%)	4.95%
Float	886,122

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.16
Forward PS	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	14.30
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.07

Current Ratio	0.07
Quick Ratio	0.04
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-29.26

Financial Efficiency

Return on equity (ROE) is -27,725.96% and return on invested capital (ROIC) is -144.87%.

Return on Equity (ROE)	-27,725.96%
Return on Assets (ROA)	-57.20%
Return on Invested Capital (ROIC)	-144.87%
Return on Capital Employed (ROCE)	3,029.33%
Revenue Per Employee	$40,143
Profits Per Employee	-$687,573
Employee Count	36
Asset Turnover	0.05
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -84.85% in the last 52 weeks. The beta is 0.84, so HCW Biologics's price volatility has been lower than the market average.

Beta (5Y)	0.84
52-Week Price Change	-84.85%
50-Day Moving Average	6.87
200-Day Moving Average	14.55
Relative Strength Index (RSI)	33.23
Average Volume (20 Days)	243,644

Short Selling Information

The latest short interest is 13,034, so 0.75% of the outstanding shares have been sold short.

Short Interest	13,034
Short Previous Month	40,678
Short % of Shares Out	0.75%
Short % of Float	1.47%
Short Ratio (days to cover)	0.01

Income Statement

In the last 12 months, HCW Biologics had revenue of $1.45 million and -$24.75 million in losses. Loss per share was -$24.35.

Revenue	1.45M
Gross Profit	345,669
Operating Income	-25.95M
Pretax Income	-27.39M
Net Income	-24.75M
EBITDA	-24.59M
EBIT	-25.95M
Loss Per Share	-$24.35

Full Income Statement

Balance Sheet

The company has $1.11 million in cash and $13.94 million in debt, giving a net cash position of -$12.83 million or -$7.36 per share.

Cash & Cash Equivalents	1.11M
Total Debt	13.94M
Net Cash	-12.83M
Net Cash Per Share	-$7.36
Equity (Book Value)	-8.56M
Book Value Per Share	-7.62
Working Capital	-25.25M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$14.14 million and capital expenditures -$131,908, giving a free cash flow of -$14.27 million.

Operating Cash Flow	-14.14M
Capital Expenditures	-131,908
Free Cash Flow	-14.27M
FCF Per Share	-$8.19

Full Cash Flow Statement

Margins

Gross Margin	23.92%
Operating Margin	-1,795.79%
Pretax Margin	-1,712.81%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

HCW Biologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.11%
Shareholder Yield	-12.11%
Earnings Yield	-315.70%
FCF Yield	-181.99%

Analyst Forecast

The average price target for HCW Biologics is $35.00, which is 677.78% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$35.00
Price Target Difference	677.78%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	171.41%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on April 11, 2025. It was a reverse split with a ratio of 0.025:1.

Last Split Date	Apr 11, 2025
Split Type	Reverse
Split Ratio	0.025:1

Scores

HCW Biologics has an Altman Z-Score of -9.38 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-9.38
Piotroski F-Score	2